Zobrazeno 1 - 10
of 67
pro vyhledávání: ''
Autor:
Young Ho Lee, Yoon Kyoung Sung
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:984-992
What is known and objective Both biologic and Janus kinase (JAK) inhibitor therapies have demonstrated substantial effectiveness in placebo-controlled studies in patients with active rheumatoid arthritis (RA) showing inadequate responses to tumour ne
Autor:
Félix López Cadenas, Laura Mezquita, María A Amores Martín, Roberto A. Escala-Cornejo, Luis Figuero-Pérez, Juan Jesús Cruz Hernández, Felipe Gómez-Caminero López, María Del Rosario Vidal Tocino, Alejandro Olivares-Hernández, Lorena Bellido Hernández
Publikováno v:
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine, Vol 2021 (2021)
Case Reports in Oncological Medicine, Vol 2021 (2021)
Background. Immunotherapy represents one of the fundamental treatments in the management of some types of cancer, especially malignant melanoma. Toxicity derived from increased immune system activity can manifest in multiple organs and systems. We pr
Publikováno v:
Journal of Oncology
Journal of Oncology, Vol 2020 (2020)
Journal of Oncology, Vol 2020 (2020)
Despite the recent advances in the biological understanding of breast cancer (BC), chemotherapy still represents a key component in the armamentarium for this disease. Different agents are available as mono-chemotherapy options in patients with local
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:35-49
What is known and objective Metastatic renal cell carcinoma (mRCC) is the most common type of kidney cancers. Disease-specific survival for mRCC has been significantly improved with the introduction of new targeted agents since 2005. However, there i
Publikováno v:
Journal of Oncology, Vol 2020 (2020)
Journal of Oncology
Journal of Oncology
Aim. We aimed to explore the effects of Bupleuri Radix (BR) on the recurrence of resected colonic polyp (CP) by measuring angiogenin-2-induced protein kinase B (Ang PKB)/Akt signaling. Method. The main ingredients of BR were extracted by using ethano
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 46:310-318
What is known and objective The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients diagnosed with non-small-cell lung cancer (NSCLC) has been confirmed by a large number of studies. However, hepatotoxicity
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics. 45:1501-1504
What is known and objective A large proportion of recurrent cervical cancer (RCC) patients present with poor performance status (PS) after comprehensive treatments, which usually prevents them from opting for clinical trials. We retrospectively analy
Autor:
Luisa Londoño-Tobón, Diego Polania-Tovar, Eduardo Orrego-González, Alberto Vélez van Meerbeke, Ana Valencia-Cárdenas, José Ardila-González
Publikováno v:
Evidence-Based Complementary and Alternative Medicine, Vol 2020 (2020)
Evidence-based Complementary and Alternative Medicine : eCAM
Evidence-based Complementary and Alternative Medicine : eCAM
Objective. Colorectal cancer represents a heavy burden for health systems worldwide, being the third most common cancer worldwide. Despite the breakthroughs in medicine, current chemotherapeutic options continue to have important side effects and may
Publikováno v:
The Breast Journal. 26:1717-1728
Background The best regimen of neo-adjuvant therapy for triple-negative breast cancer (TNBC) is unknown. Recent studies have shown promising data that adding carboplatin or pembrolizumab improves the rate of pathologic complete response (pCR) in TNBC
Autor:
Nikolaos Kanellias, Evangelos Terpos, Efstathios Kastritis, Maria Gavriatopoulou, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou
Publikováno v:
Journal of Oncology
Journal of Oncology, Vol 2020 (2020)
Journal of Oncology, Vol 2020 (2020)
Panobinostat represents a potent oral nonselective pan-histone deacetylase inhibitor (HDAC) with activity in myeloma patients. It has been approved by the FDA and EMA in combination with bortezomib and dexamethasone for the treatment of multiple myel